Greenwich LifeSciences (GLSI) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free GLSI Stock Alerts $14.83 +1.42 (+10.59%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26, 2024 | finance.yahoo.comGreenwich LifeSciences, Inc. (GLSI)May 25, 2024 | americanbankingnews.comFY2024 EPS Estimates for Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Boosted by HC WainwrightMay 24, 2024 | marketbeat.comHC Wainwright Brokers Lift Earnings Estimates for Greenwich LifeSciences, Inc. (NASDAQ:GLSI)Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Greenwich LifeSciences in a report issued on Wednesday, May 22nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnMay 24, 2024 | americanbankingnews.comHC Wainwright Weighs in on Greenwich LifeSciences, Inc.'s Q1 2025 Earnings (NASDAQ:GLSI)May 23, 2024 | marketbeat.comGreenwich LifeSciences, Inc. Expected to Earn Q1 2025 Earnings of ($0.17) Per Share (NASDAQ:GLSI)Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Greenwich LifeSciences in a research note issued to investors on Wednesday, May 22nd. HC Wainwright analyst Y. Chen forecasts thatMay 23, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI)May 22, 2024 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research report on Wednesday.May 20, 2024 | investorplace.comGLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024April 15, 2024 | markets.businessinsider.comGLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023April 4, 2024 | insidertrades.comSnehal Patel Buys 3,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockApril 3, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $57,240.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 3,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were acquired at an average cost of $19.08 per share, with a total value of $57,240.00. Following the completion of the transaction, the chief executive officer now directly owns 5,350,777 shares in the company, valued at approximately $102,092,825.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 27, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,500 SharesMarch 26, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $49,950.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 2,500 shares of the stock in a transaction on Friday, March 22nd. The stock was acquired at an average price of $19.98 per share, with a total value of $49,950.00. Following the completion of the acquisition, the chief executive officer now owns 5,347,777 shares of the company's stock, valued at approximately $106,848,584.46. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.March 23, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,500 SharesMarch 16, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,100 SharesMarch 13, 2024 | globenewswire.comGreenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025March 12, 2024 | globenewswire.comGreenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in EuropeMarch 7, 2024 | finance.yahoo.comGreenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional SharesMarch 6, 2024 | marketbeat.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 4,100 Shares of StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,100 shares of the business's stock in a transaction that occurred on Monday, March 4th. The shares were purchased at an average price of $13.03 per share, with a total value of $53,423.00. Following the completion of the acquisition, the chief executive officer now owns 5,340,277 shares of the company's stock, valued at approximately $69,583,809.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 2, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) Forecasted to Post Q1 2024 Earnings of ($0.20) Per ShareGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Greenwich LifeSciences in a note issued to investors on Wednesday, February 28th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.2February 28, 2024 | markets.businessinsider.comExpanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-EuropeanFebruary 27, 2024 | msn.comGreenwich LifeSciences stock jumps 8% on Phase 3 study expansionFebruary 27, 2024 | finanznachrichten.deGreenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesFebruary 27, 2024 | globenewswire.comGreenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesFebruary 23, 2024 | benzinga.comGreenwich LifeSciences Stock (NASDAQ:GLSI) Dividends: History, Yield and DatesFebruary 22, 2024 | finanznachrichten.deGreenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European RegulatorsFebruary 22, 2024 | msn.comGreenwich Lifesciences announces acceptance for Flamingo-01 trial by EMAFebruary 22, 2024 | finance.yahoo.comGreenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European RegulatorsFebruary 22, 2024 | marketbeat.comHC Wainwright Weighs in on Greenwich LifeSciences, Inc.'s FY2023 Earnings (NASDAQ:GLSI)Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Investment analysts at HC Wainwright boosted their FY2023 EPS estimates for shares of Greenwich LifeSciences in a research note issued on Tuesday, February 20th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.6February 22, 2024 | globenewswire.comGreenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European RegulatorsFebruary 21, 2024 | realmoney.thestreet.com2 Rare Insider Buys in a Frothy MarketFebruary 21, 2024 | marketbeat.comBrokers Offer Predictions for Greenwich LifeSciences, Inc.'s FY2024 Earnings (NASDAQ:GLSI)Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Greenwich LifeSciences in a research note issued to investors on Tuesday, February 20th. HC Wainwright analyst Y. Chen forecasts that the company will post earFebruary 20, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Greenwich LifeSciences: Here's What You Need To KnowFebruary 20, 2024 | marketbeat.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 12,700 Shares of StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 12,700 shares of the business's stock in a transaction on Thursday, February 15th. The shares were bought at an average price of $11.07 per share, for a total transaction of $140,589.00. Following the purchase, the chief executive officer now directly owns 5,325,377 shares in the company, valued at approximately $58,951,923.39. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.February 20, 2024 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) PT Lowered to $36.00 at HC WainwrightHC Wainwright cut their target price on shares of Greenwich LifeSciences from $38.00 to $36.00 and set a "buy" rating for the company in a report on Tuesday.February 14, 2024 | msn.comWhy Greenwich Lifesciences (GLSI) Stock Is SkyrocketingFebruary 14, 2024 | morningstar.comGreenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer ImmunotherapyFebruary 14, 2024 | globenewswire.comGreenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01December 21, 2023 | bbc.co.ukGreenwich: Closed pub reopens as community hubDecember 11, 2023 | finance.yahoo.comInsiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recentlyDecember 2, 2023 | yahoo.comGreenwich, United States - Weather Forecasts | Maps | News - Yahoo WeatherNovember 21, 2023 | finanznachrichten.deGreenwich LifeSciences, Inc.: Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024November 21, 2023 | finance.yahoo.comGreenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024November 14, 2023 | finance.yahoo.comGreenwich LifeSciences Insiders Added US$653.7k Of Stock To Their HoldingsNovember 1, 2023 | chron.comGreenwich election guide 2023: Meet the candidates running for officeSeptember 20, 2023 | theguardian.comUniversity of GreenwichSeptember 13, 2023 | finance.yahoo.comInsider Buying: Snehal Patel Acquires 1,000 Shares of Greenwich LifeSciences IncSeptember 1, 2023 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest UpdateGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 187,000 shares, a growth of 5.2% from the July 31st total of 177,800 shares. Based on an average daily volume of 19,800 shares, the short-interest ratio is presently 9.4 days. Currently, 3.2% of the company's stock are short sold.July 1, 2023 | greenwichtime.comGreenwich's dual July 4th fireworks displays: Where, when and everything else you need to knowJune 27, 2023 | finance.yahoo.comGLSI - Greenwich LifeSciences, Inc. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Are You Positioned For The New Energy Goldrush? (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. GLSI Media Mentions By Week GLSI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLSI News Sentiment▼0.910.76▲Average Medical News Sentiment GLSI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLSI Articles This Week▼31▲GLSI Articles Average Week Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PBYI News Today ALXO News Today CALT News Today DNTH News Today SLN News Today ANAB News Today AVBP News Today HROW News Today PHAR News Today ABUS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLSI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
